Apotex Pty Limited Pharmaceutical Import Profile — Australia (DGFT 2022–2026)

Name: Apotex Pty Limited Pharmaceutical Import Records from India — 17 Products, $22.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Apotex Pty Limited — Pharmaceutical Importer Profile (2026) | 17 Products, $22.3M Trade | TransData Nexus

Apotex Pty Limited

Pharmaceutical Importer · Australia · Cardiovascular Focus · $22.3M Total Trade · DGFT Verified

Apotex Pty Limited is a pharmaceutical importer based in Australia with a total trade value of $22.3M across 17 products in 9 therapeutic categories. Based on 516 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Apotex Pty Limited sources from 22 verified Indian suppliers, with Strides Pharma Science Limited accounting for 36.8% of imports.

Apotex Pty Limited — Import Portfolio & Supplier Network

Apotex Pty Limited import network — 17 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Apotex Pty Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Strides Pharma Science Limited	$5.3M	167	36.8%
Alembic Pharmaceuticals Limited	$3.2M	145	21.9%
Intas Pharmaceuticals Limited

What Formulations Does Apotex Pty Limited Import?

Formulation	Value	Ships
Apx-rosuvastatin rosuvastatin tablets	$450.0K	9
Apx-rosuvastatin rosuvastatin tablets	$322.4K	7
Desvenlafaxine benzoate er 50mg28aus apodesvenlafaxine benzoate extended release tablets others-medicine put up for	$280.1K	6
Apx-rosuvastatin rosuvastatin tablets	$231.8K	5
Metaraminol solutionfor injection10mg/1mlmetaraminol	$200.0K	4
Duloxetine CAPS. 60	$170.9K	9
Apx-amitriptyline amitriptyline	$158.1K	5
"others"- pharma : apo-ezetimibe/simvastatin 10/20 tablets ezetimibe 10MG+simvastatin 20MG - 01 nos = size 3x10	$150.0K	3
Apx-rosuvastatin rosuvastatin tablets [20MG] (128991.00 x 3 x 10's	$150.0K	3
Apx-valaciclovir valaciclovir tablets 500MG [fc] (27457.00 x 3 x 10s	$150.0K	3
Metaraminol solution for injection10mg/1ML (metaraminol apotex)	$150.0K	3
Apo duloxetine 60MG capsules duloxetinecapsules 60MG [4 x 7 CAPS per	$137.4K	5
Apx-rosuvastatin rosuvastatin tablets	$137.1K	4
Apo telmisartan 80MG tabs 4x7's	$134.9K	3
Apx-mirtazapine apx-mirtazapine	$124.6K	3

Apotex Pty Limited imports 336 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 17 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Rosuvastatin	Cardiovascular	$6.2M	123	1.3%	4
2	Irbesartan	Cardiovascular	$5.0M	106	2.7%	7
3	Telmisartan	Cardiovascular	$1.6M	32	0.0%	7
4	Sertraline	CNS & Psychiatric	$1.5M	30	0.3%	17
5	Fexofenadine	Antihistamines & Allergy	$1.3M	44	1.2%	20
6	Ezetimibe	Lipid & Metabolism	$1.3M	25	0.2%	16
7	Doxycycline	Antibiotics	$1.0M	25	0.9%	13
8	Simvastatin	Cardiovascular	$750.0K	15	0.6%	10
9	Fluoxetine	CNS & Psychiatric	$700.0K	14	0.3%	14
10	Propranolol	Cardiovascular	$700.0K	14	1.2%	4
11	Pravastatin	Cardiovascular	$501.2K	15	1.6%	10
12	Mycophenolate	Immunosuppressants	$500.0K	10	0.1%	4
13	Allopurinol	Lipid & Metabolism	$400.0K	8	0.1%	14
14	Roxithromycin	Advanced Antibiotics	$328.9K	20	4.4%	3
15	Meloxicam	Analgesics & Antipyretics	$288.3K	19	0.1%	13
16	Metoclopramide	Gastrointestinal	$200.1K	6	0.9%	11
17	Norfloxacin	Advanced Antibiotics	$127.9K	10	1.5%	8

Apotex Pty Limited imports 17 pharmaceutical products across 9 categories into Australia totaling $22.3M.

Apotex Pty Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Apotex Pty Limited is an Australian proprietary company specializing in the importation and distribution of pharmaceutical products. Established on November 8, 1991, with Australian Company Number (ACN) 054 124 980 and Australian Business Number (ABN) 48 054 124 980, the company is headquartered in New South Wales, Australia. As a subsidiary of Apotex Inc., a Canadian global pharmaceutical company founded in 1974, Apotex Pty Limited plays a pivotal role in supplying generic pharmaceuticals, over-the-counter (OTC) products, and vitamins to the Australian market.

Apotex Inc. is renowned for its extensive portfolio, offering over 2,500 registered products across various therapeutic areas, including prescription medications, OTC products, and complementary medicines. (tga.gov.au) This comprehensive range underscores Apotex Pty Limited's commitment to enhancing access to affordable and high-quality healthcare solutions within Australia.

2Distribution Network

Apotex Pty Limited's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across Australia. While specific warehouse locations are not publicly disclosed, the company's logistics capabilities are robust, facilitating timely and reliable distribution to pharmacies, hospitals, and healthcare providers nationwide. The geographic coverage extends beyond Australia, leveraging Apotex Inc.'s global manufacturing facilities in Canada, Mexico, and India to source a diverse range of pharmaceutical products.

3Industry Role

In Australia's pharmaceutical supply chain, Apotex Pty Limited functions primarily as a wholesaler and distributor. By importing a wide array of generic pharmaceuticals and OTC products, the company ensures the availability of cost-effective alternatives to brand-name medications. This role is crucial in maintaining a competitive market landscape and providing consumers with accessible healthcare options. Apotex Pty Limited's operations also support the Pharmaceutical Benefits Scheme (PBS), contributing to the sustainability of Australia's healthcare system. (tga.gov.au)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Apotex Pty Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Apotex Pty Limited's sourcing strategy exhibits a notable concentration on Indian pharmaceutical suppliers. Between 2022 and 2026, the company imported finished pharmaceutical formulations valued at $22.3 million USD from India, encompassing 516 shipments across 17 products in 9 therapeutic categories. The top five imported products—Rosuvastatin, Irbesartan, Telmisartan, Sertraline, and Fexofenadine—accounted for 69.6% of the total import value, indicating a high degree of portfolio concentration.

This sourcing pattern suggests a strategic choice to leverage India's competitive manufacturing capabilities and cost advantages. The reliance on a select group of suppliers, including STRIDES PHARMA SCIENCE LIMITED and ALEMBIC PHARMACEUTICALS LIMITED, may enhance negotiation leverage and streamline logistics. However, such concentration also introduces risks related to supply chain disruptions, regulatory changes, or quality control issues within these suppliers.

2Supply Chain Resilience

Apotex Pty Limited's supply chain resilience is influenced by its concentrated sourcing from Indian suppliers. The company's portfolio includes 336 unique formulations, indicating a diverse product range. However, the heavy reliance on a limited number of suppliers for key products could pose challenges in the event of supply disruptions. To mitigate these risks, it is essential for Apotex Pty Limited to establish contingency plans, diversify its supplier base, and maintain robust quality assurance processes. Ensuring that all suppliers adhere to international Good Manufacturing Practice (GMP) standards is crucial for maintaining product quality and regulatory compliance.

Importing Pharmaceuticals into Australia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Australia

1Regulatory Authority & Framework

In Australia, the Therapeutic Goods Administration (TGA) is the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The TGA ensures that medicines and medical devices meet stringent safety, efficacy, and quality standards before they are made available to the public. Key legislation governing pharmaceutical imports includes the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990, which outline the requirements for product registration, manufacturing practices, and post-market surveillance.

For Indian generics to be marketed in Australia, they must undergo a rigorous evaluation process by the TGA. This process involves submitting comprehensive data on the product's quality, safety, and efficacy, as well as evidence of compliance with Good Manufacturing Practice (GMP) standards. The TGA assesses this information to determine whether the product can be included in the Australian Register of Therapeutic Goods (ARTG), which is a prerequisite for legal marketing and distribution within the country.

2Import Licensing & GMP

Import licensing in Australia is managed by the TGA, which requires that all imported pharmaceutical products be included in the ARTG. Manufacturers and sponsors must provide evidence of GMP compliance, typically through certificates issued by recognized authorities such as the European Medicines Agency (EMA), World Health Organization (WHO), or the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications ensure that manufacturing processes meet international standards for product quality and safety.

Apotex Pty Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Apotex Pty Limited's focus on importing products in the cardiovascular, CNS, and lipid metabolism therapeutic areas aligns with significant market demand in Australia. Cardiovascular diseases remain a leading cause of morbidity and mortality, driving the need for effective and affordable treatments. Similarly, CNS disorders and lipid metabolism issues are prevalent, necessitating a steady supply of therapeutic options. By concentrating on these areas, Apotex Pty Limited addresses critical health concerns and positions itself as a key supplier in these segments.

2Sourcing Profile

Apotex Pty Limited's sourcing strategy emphasizes generic drug procurement, leveraging India's manufacturing capabilities to provide cost-effective alternatives to branded medications. The company's preference for finished pharmaceutical formulations over raw Active Pharmaceutical Ingredients (APIs) allows for streamlined logistics and faster market entry. India's adherence to international GMP standards and its PIC/S membership further enhance the reliability and quality of the sourced products.

3Market Positioning

Apotex Pty Limited serves a broad segment of the Australian pharmaceutical market, including retail pharmacies, hospitals, and government tenders. By offering a diverse range of generic pharmaceuticals and OTC products, the company caters to various healthcare needs, ensuring that patients have access to affordable and effective treatments across different settings.

Seller's Guide — How to Become a Supplier to Apotex Pty Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Apotex Pty Limited, especially those offering high-quality generic products that meet Australian regulatory standards. Gaps in Apotex Pty Limited's current sourcing may exist in emerging therapeutic areas or products with unmet market needs. Indian exporters can explore these opportunities by ensuring compliance with TGA requirements and demonstrating the value proposition of their products.

2Requirements & Qualifications

Indian exporters aiming to supply Apotex Pty Limited and the Australian market must obtain GMP certifications from recognized authorities such as the EMA, WHO, or PIC/S. Additionally, they must ensure that their products are registered with the TGA and included in the ARTG. Compliance with Australian labeling requirements, including English language labeling and adherence to serialization mandates, is also essential.

3How to Approach

To establish a relationship with Apotex Pty Limited, Indian exporters should initiate contact through formal channels, presenting their product portfolios and demonstrating compliance with Australian regulatory standards. Participating in relevant tenders and industry

Frequently Asked Questions — Apotex Pty Limited

What products does Apotex Pty Limited import from India?

Apotex Pty Limited imports 17 pharmaceutical products across 9 categories. Top imports: Rosuvastatin ($6.2M), Irbesartan ($5.0M), Telmisartan ($1.6M), Sertraline ($1.5M), Fexofenadine ($1.3M).

Who supplies pharmaceuticals to Apotex Pty Limited from India?

Apotex Pty Limited sources from 22 verified Indian suppliers. The primary supplier is Strides Pharma Science Limited (36.8% of imports, $5.3M).

What is Apotex Pty Limited's total pharmaceutical import value?

Apotex Pty Limited's total pharmaceutical import value from India is $22.3M, based on 516 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Apotex Pty Limited focus on?

Apotex Pty Limited imports across 9 categories. The largest: Cardiovascular (65.8%), CNS & Psychiatric (9.8%), Lipid & Metabolism (7.4%).

Get Full Apotex Pty Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 6 company name variants from customs records. For current shipment-level data, contact TransData Nexus.